📚 Central Nervous System Special Senses Module L5 Antiseizure I

📚 Lecture Overview

This lecture covers the pharmacology of first- and second-generation Antiseizure Drugs (ASDs). It focuses on their mechanisms of action, pharmacokinetic properties, therapeutic indications, and adverse effect profiles. Understanding these concepts is critical for choosing the correct therapy and managing drug-drug interactions in clinical practice.

🎯 Key Concepts & Definitions

• Antiseizure Drugs (ASDs): Medications that prevent or suppress the generation, propagation, and severity of epileptic seizures. They provide symptomatic treatment only and do not alter the underlying course of epilepsy.
• Use-Dependent Blockade: A mechanism where a drug preferentially binds to sodium channels in their rapidly firing (active) state, slowing channel recovery and preventing high-frequency abnormal electrical propagation.
• Idiosyncratic Adverse Reactions: Unpredictable, non-dose-dependent drug reactions linked to genetic vulnerability (e.g., severe skin rashes, blood dyscrasias, and liver damage).
• Broad-Spectrum ASDs: Medications effective against multiple types of seizures (e.g., Valproate, Topiramate, Levetiracetam).

📖 Main Content

1. Classification of Antiseizure Drugs (ASDs)

• First Generation ASDs:
  • Carbamazepine
  • Phenytoin
  • Ethosuximide
  • Sodium valproate (Valproic acid)
• Second Generation ASDs:
  • Gabapentin
  • Pregabalin
  • Lamotrigine
  • Levetiracetam
  • Topiramate

2. Pharmacokinetic Properties

• Absorption & Distribution: ASDs are well absorbed orally with high bioavailability. They are typically small, lipophilic, and uncharged to cross the blood-brain barrier (BBB) via passive diffusion.
• Protein Binding: Some ASDs, such as Valproate and Phenytoin, exhibit high plasma protein binding, which increases the risk of drug-drug interactions.
• Metabolism: Most ASDs are metabolized by hepatic cytochrome P450 enzymes. Several function via active metabolites.
• Excretion: Drugs excreted unchanged in the urine require dose modifications in patients with renal impairment. These include:
  • Gabapentin
  • Pregabalin
  • Levetiracetam
• Dosing: Most ASDs have long half-lives, allowing for once- or twice-daily dosing.

3. Mechanisms of Action

ASDs inhibit local seizure generation and prevent the spread of electrical activity through several molecular targets:
* Sodium (Na+) Channel Blockade (Use-Dependent): Slows the recovery of rapidly firing sodium channels.
* Examples: Carbamazepine, Lamotrigine
* Calcium (Ca2+) Channel Blockade: Blocks voltage-dependent calcium channels to decrease synaptic vesicle release.
* Examples: Ethosuximide, Gabapentin
* Synaptic Vesicle Recycling Interference: Inhibits the synaptic vesicle protein 2A (SV2A), reducing the exocytosis of the excitatory neurotransmitter glutamate during high-frequency activity.
* Example: Levetiracetam
* GABA Neurotransmission Enhancement:
* GABA Receptor Agonism: Opens chloride channels, causing neuronal hyperpolarization (e.g., Benzodiazepines, Barbiturates).
* GABA Synthesis & Degradation: Promotes GABA formation and inhibits its breakdown (e.g., Valproate).
* Glutamate Neurotransmission Inhibition: Reduces excitatory signaling.
* Examples: Topiramate, Pregabalin, Gabapentin

4. Therapeutic Indications

• Epilepsy: Therapy should begin with an appropriate monotherapy tailored to the patient.
  • Absence Seizures: Specifically treated with Ethosuximide (Ca2+ channel blocker).
  • Broad Spectrum: Valproate, Topiramate, and Levetiracetam.
• Neuropathic Pain: Used for diabetic neuropathy and post-herpetic neuralgia.
  • Preferred Drugs: Pregabalin and Gabapentin.
• Trigeminal Neuralgia: Carbamazepine is the drug of choice with the strongest evidence of efficacy.
• Bipolar Affective Disorder: Used as mood stabilizers.
  • Preferred Drugs: Valproic acid, Lamotrigine, and Carbamazepine.
• Migraine Prophylaxis: Used between attacks to reduce severity and frequency.
  • Preferred Drugs: Topiramate and Valproic acid.

5. Adverse Reactions

• Dose-Dependent Reactions: The most common adverse events. They have a known mechanism, occur during drug initiation or dose escalation, and typically resolve with continued therapy or dose reduction.
  • Symptoms: Sedation, ataxia, and dizziness.
  • Special Note: Levetiracetam can cause serious but less common behavioral and mood changes.
• Idiosyncratic Reactions: Unpredictable and genetically driven.
  • Symptoms: Skin rashes, blood dyscrasias (e.g., pancytopenia), and hepatotoxicity.
  • Clinical Action: If a skin rash develops during Lamotrigine therapy, the drug must be stopped immediately.
• Chronic Reactions: Occur after long-term use.

📊 Visual Learning

Diagram 1: Mechanisms of Action Pathways

Diagram 2: Clinical Indications Mind Map

💡 Important Points to Remember

• ASDs are symptomatic treatments only; they do not cure epilepsy or alter disease progression.
• To cross the BBB, ASDs must be small, lipophilic, and uncharged.
• Valproate and Phenytoin are highly protein-bound, which frequently leads to displacement interactions with other drugs.
• Gabapentin, Pregabalin, and Levetiracetam are excreted unchanged in the urine; their doses must be reduced in patients with renal impairment.
• Ethosuximide is highly specific for absence seizures and works by blocking voltage-dependent calcium channels.
• Levetiracetam targets the SV2A protein to inhibit glutamate release.
• Carbamazepine is the primary drug of choice for trigeminal neuralgia.
• A skin rash during Lamotrigine treatment is a dangerous idiosyncratic reaction requiring immediate discontinuation.
• Dose-dependent side effects (sedation, ataxia, dizziness) are common when starting therapy but usually improve over time.

⚠️ Common Exam Questions & Traps

How Examiners Trick Students:

• The "Cure" Lie: Examiners may ask if ASDs "delay the progression" or "cure" epilepsy. Remember: ASDs only suppress seizure symptoms; they do not alter the disease course.
• Renal Impairment Trap: A question might present a patient with renal failure and ask which drug requires a dose adjustment. Remember that Gabapentin, Pregabalin, and Levetiracetam are excreted unchanged by the kidneys and need dose modifications. Conversely, Phenytoin and Valproate are metabolized hepatically and are safer options without renal adjustments.
• The Lamotrigine Rash Trap: Questions may suggest waiting to see if a Lamotrigine-induced rash goes away, or reducing the dose. This is a trap! Any skin rash with Lamotrigine requires immediate discontinuation due to the risk of severe idiosyncratic reactions.
• Mechanism Matching: Examiners often switch the mechanisms of Ethosuximide and Carbamazepine. Remember: Ethosuximide blocks Calcium channels; Carbamazepine blocks Sodium channels.

Common Exam Traps Table

📝 Quick Review Checklist

I can explain why "antiseizure" is preferred over "antiepileptic" or "anticonvulsant."
I can list the drugs that require dose modification in renal impairment.
I can identify which two major ASDs have high plasma protein binding.
I understand the mechanism of action of Levetiracetam (SV2A inhibition).
I know the drug of choice for trigeminal neuralgia (Carbamazepine).
I know how to manage a patient who develops a rash while taking Lamotrigine.
I can distinguish between dose-dependent side effects and idiosyncratic reactions.